HUTCHMED (China) Limited (HCM) Stock

HUTCHMED (China) Limited is a dynamic biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, both domestically in Hong Kong and globally.

Operating through its Oncology/Immunology and Other Ventures segments, HUTCHMED leads with a robust pipeline that includes Savolitinib, targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Additionally, the company is advancing Fruquintinib, designed to treat CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and various gastrointestinal and solid tumors. Another key development is Surufatinib, addressing neuroendocrine tumors (NET), pancreatic NET, biliary tract cancer, sarcoma, and a wide spectrum of other solid tumors.

Further bolstering its portfolio, HUTCHMED is progressing HMPL-523, an inhibitor targeting spleen tyrosine kinase for hematological cancers and chronic immune diseases, alongside a range of other promising candidates such as Tazemetostat for specific sarcoma and lymphoma patients, and HMPL-306 for hematological malignancies and solid tumors. The company also collaborates extensively with leading entities including AstraZeneca AB, Lilly (Shanghai) Management Company Limited, BeiGene, and Epizyme, Inc., underscoring its commitment to advancing cutting-edge therapies. Founded in 2000 and headquartered in Central, Hong Kong, HUTCHMED (China) Limited formerly known as Hutchison China MediTech Limited continues to drive innovation in biopharmaceuticals with a global impact.